Genetic and ethnic risk factors associated with drug hypersensitivity

Current Opinion in Allergy and Clinical Immunology

Volumn 10, Issue 4, 2010, Pages 280-290

  Kim, Seung Hyun ^a   Ye, Young Min ^a   Palikhe, Nami Shrestha ^a   Kim, Jeong Eun ^a   Park, Hae Sim ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

antibiotics; anticonvulsant agent; antitubercular agent; aspirin; drug hypersensitivity

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ALLOPURINOL; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CYTOCHROME P450 2E1; GLUTATHIONE TRANSFERASE; HISTAMINE; HLA B ANTIGEN; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4 RECEPTOR; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; TUBERCULOSTATIC AGENT;

CAUCASIAN; CELL INFILTRATION; CHINESE; DRUG HYPERSENSITIVITY; EOSINOPHIL; ETHNICITY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; IMMUNE FUNCTION TEST; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STEVENS JOHNSON SYNDROME; TOXIC HEPATITIS; ADVERSE DRUG REACTION; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNOLOGY; GENETICS;

ASIAN CONTINENTAL ANCESTRY GROUP; DRUG HYPERSENSITIVITY; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; PHARMACEUTICAL PREPARATIONS; RISK FACTORS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS;

EID: 77954660609     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32833b1eb3     Document Type: Review

References (113)

1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-1205.
2. Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of theNomenclature Review Committee of theWorld Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832-836. (Pubitemid 38608590)
3. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209:123-129.
4. Naisbitt DJ, Pirmohamed M, Park BK. Immunopharmacology of hypersensitivity reactions to drugs. Curr Allergy Asthma Rep 2003; 3:22-29.
5. Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B-5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-819.
6. Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16:432-436.
7. Hedman J, Kaprio J, Poussa T, Nieminen MM. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28:717-722.
8. Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347:1493-1499.
9. Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000; 161:391-398.
10. Setkowicz M, Mastalerz L, Podolec-Rubis M, et al. Clinical course and urinary eicosanoids in patients with aspirin-induced urticaria followed up for 4 years. J Allergy Clin Immunol 2009; 123:174-178.
11. Sanak M, Pierzchalska M, Bazan-Socha S, Szczeklik A. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23:290-296.
12. Kim SH, Oh JM, Kim YS, et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy 2006; 36:433-439.
13. Park JS, Chang HS, Park CS, et al. Association analysis of cysteinylleukotriene receptor 2 (CYSLTR2) polymorphisms with aspirin intolerance in asthmatics. Pharmacogenet Genom 2005; 15:483-492.
14. Kim SH, Kim YK, Park HW, et al. Association between polymorphisms in prostanoid receptor genes and aspirin-intolerant asthma. Pharmacogenet Genom 2007; 17:295-304.
15. Szczeklik W, Sanak M, Szczeklik A. Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma. J Allergy Clin Immunol 2004; 114:248-253.
16. Choi JH, Lee KW, Oh HB, et al. HLA association in aspirin-intolerant asthma: DPB1-0301 as a strong marker in a Korean population. J Allergy Clin Immunol 2004; 113:562-564.
17. Kim SH, Choi JH, Park HS, et al. Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma. Clin Exp Allergy 2005; 35:585-590.
18. Kim SH, Yang EM, Lee HN, et al. Association of the CCR3 gene polymorphism with aspirin exacerbated respiratory disease. Respir Med 2009; 104: 626-632.
19. Palikhe NS, Kim SH, Cho BY, et al. Genetic variability in CRTH2 polymorphism increases eotaxin-2 levels in patients with aspirin exacerbated respiratory disease. Allergy 2009; 65:338-346.
20. Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109:936-942.
21. Van Sambeek R, Stevenson DD, Baldasaro M, et al. 50 flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000; 106:72-76.
22. Choi JH, Kim SH, Bae JS, et al. Lack of an association between a newly identified promoter polymorphism (-1702G > A) of the leukotriene C4 synthase gene and aspirin-intolerant asthma in a Korean population. Tohoku J Exp Med 2006; 208:49-56.
23. Pillai SG, Cousens DJ, Barnes AA, et al. A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics 2004; 14:627-633.
24. Fukai H, Ogasawara Y, Migita O, et al. Association between a polymorphism in cysteinyl leukotriene receptor 2 on chromosome 13q14 and atopic asthma. Pharmacogenetics 2004; 14:683-690.
25. Jinnai N, Sakagami T, Sekigawa T, et al. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet 2004; 13:3203-3217.
26. Dekker JW, Nizankowska E, Schmitz-Schumann M, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 1997; 27:574-577.
27. Sanchez-Borges M, Acevedo N, Vergara C, et al. The A-444C polymorphism in the leukotriene C4 synthase gene is associated with aspirin-induced urticaria. J Investig Allergol Clin Immunol 2009; 19:375-382.
28. Bae JS, Kim SH, Ye YM, et al. Significant association of FcepsilonRIalpha promoter polymorphisms with aspirin-intolerant chronic urticaria. J Allergy Clin Immunol 2007; 119:449-456.
29. Palikhe N, Kim SH, Yang EM, et al. Analysis of high-affinity IgE receptor (FcepsilonR1) polymorphisms in patients with aspirin-intolerant chronic urticaria. Allergy Asthma Proc 2008; 29:250-257.
30. Kim SH, Kang YM, Cho BY, et al. Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acidintolerant chronic urticaria. Allergy 2009; 64:213-221.
31. Choi JH, Kim SH, Cho BY, et al. Association of TNF-alpha promoter polymorphisms with aspirin-induced urticaria. J Clin Pharm Ther 2009; 34:231-238.
32. Kim SH, Choi JH, Lee KW, et al. The human leucocyte antigen-DRB1-1302- DQB1-0609-DPB1-0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy 2005; 35:339-344.
33. Sanak M, Potaczek DP, Mastalerz L, et al. FCERIA gene promoter polymorphisms: lack of association with aspirin hypersensitivity in whites. J Allergy Clin Immunol 2007; 119:1280-1281.
34. Choi JH, Kim SH, Suh CH, et al. Polymorphisms of high-affinity IgE receptor and histamine-related genes in patients with ASA-induced urticaria/angioedema. J Korean Med Sci 2005; 20:367-372.
35. O'Donnell BF, O'Neill CM, Francis DM, et al. Human leucocyte antigen class II associations in chronic idiopathic urticaria. Br J Dermatol 1999; 140:853-858.
36. Madaan A, Li JT. Cephalosporin allergy. Immunol Allergy Clin North Am 2004; 24:463-476; vi-vii.
37. Thong BY. Update on the management of antibiotic allergy. Allergy Asthma Immunol Res 2010; 2:77-86.
38. Gueant-Rodriguez RM, Romano A, Beri-Dexheimer M, et al. Gene-gene interactions of IL13 and IL4RA variants in immediate allergic reactions to betalactam antibiotics. Pharmacogenet Genom 2006; 16:713-719.
39. Guglielmi L, Fontaine C, Gougat C, et al. IL-10 promoter and IL4-Ralpha gene SNPs are associated with immediate beta-lactam allergy in atopic women. Allergy 2006; 61:921-927.
40. Huang CZ, Yang J, Qiao HL, Jia LJ. Polymorphisms and haplotype analysis of IL-4Ralpha Q576R and I75V in patients with penicillin allergy. Eur J Clin Pharmacol 2009; 65:895-902.
41. Apter AJ, Schelleman H, Walker A, et al. Clinical and genetic risk factors of self-reported penicillin allergy. J Allergy Clin Immunol 2008; 122:152-158.
42. Yang J, Qiao HL, Dong ZM. Polymorphisms of IL-13 and IL-4-IL-13-SNPs in patients with penicillin allergies. Eur J Clin Pharmacol 2005; 61:803-809.
43. Qiao HL, Yang J, Zhang YW. Relationships between specific serum IgE, cytokines and polymorphisms in the IL-4, IL-4Ralpha in patients with penicillins allergy. Allergy 2005; 60:1053-1059. (Pubitemid 40942761)
44. Qiao HL, Yang J, Zhang YW. Specific serum IgE levels and FcepsilonRIbeta genetic polymorphism in patients with penicillins allergy. Allergy 2004; 59:1326-1332.
45. Delomenie C, Grant DM, Mathelier-Fusade P, et al. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmacol 1994; 38:581-582.
46. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000; 10:705-713.
47. Alfirevic A, Stalford AC, Vilar FJ, et al. Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003; 55:158-165.
48. Wolkenstein P, Loriot MA, Flahault A, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in AIDS patients with cutaneous reactions to sulfonamides. J Invest Dermatol 2005; 125:1080-1082.
49. Schneider MM, Nielsen TL, Nelsing S, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis 1995; 171:1632-1636.
50. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47:717-720.
51. Kim SH, Lee JE, Jee YK, et al. Allelic variants of CD40 and CD40L genes interact to promote antibiotic-induced cutaneous allergic reactions. Clin Exp Allergy 2009; 39:1852-1856.
52. Zurawski SM, Vega F Jr, Huyghe B, Zurawski G. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. EMBO J 1993; 12:2663-2670.
53. Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17:701-738.
54. Graves PE, Kabesch M, Halonen M, et al. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allerg Clin Immunol 2000; 105:506-513.
55. Moore KW, De Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19:683-765.
56. Turner DM, Williams DM, Sankaran D, et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24:1-8.
57. Reuss E, Fimmers R, Kruger A, et al. Differential regulation of interleukin-10 production by genetic and environmental factors: a twin study. Genes Immun 2002; 3:407-413.
58. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005; 5:271-283.
59. Vree TB, Van Der Ven AJ, Verwey-van Wissen CP, et al. Isolation, identification and determination of sulfamethoxazole and its known metabolites in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1994; 658:327-340.
60. Romano A, De Santis A, Romito A, et al. Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann Allergy Asthma Immunol 1998; 80:433-437.
61. Pande JN, Singh SP, Khilnani GC, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51:132-136.
62. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174:935-952.
63. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477.
64. Andrade RJ, Robles M, Ulzurrun E, Lucena MI. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10:1467-1487.
65. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42:107-121.
66. Mehta S. Malnutrition and drugs: clinical implications. Dev Pharmacol Ther 1990; 15:159-165.
67. Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31:47-64.
68. Naisbitt DJ, Williams DP, Pirmohamed M, et al. Reactive metabolites and their role in drug reactions. Curr Opin Allergy Clin Immunol 2001; 1:317-325.
69. Cho HJ, Koh WJ, Ryu YJ, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87:551-556.
70. Huang YS, Chern HD, Su WJ, et al. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003; 37:924-930.
71. Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazidinduced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62:423-429.
72. Yamada S, Tang M, Richardson K, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10:1433-1445.
73. Wang T, Wang W, Wang ZY, et al. Association of P450-2E1 and GSTM1 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity. Zhonghua Jie He He Hu Xi Za Zhi 2009; 32:585-587.
74. Kim SH, Bahn JW, Kim YK, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10:1767-1779.
75. Huang YS, Chern HD, Su WJ, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 2002; 35:883-889.
76. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4:256-261.
77. Kita T, Tanigawara Y, Chikazawa S, et al. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull 2001; 24:544-549.
78. Hiratsuka M, Kishikawa Y, Takekuma Y, et al. Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients. Drug Metab Pharmacokinet 2002; 17:357-362.
79. Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the Nacetyltransferase 2 gene, is an important biomarker for risk of antituberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13:6003-6008.
80. Possuelo LG, Castelan JA, De Brito TC, et al. Association of slow Nacetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 2008; 64:673-681.
81. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4:125-134.
82. Roy B, Chowdhury A, Kundu S, et al. Increased risk of antituberculosis druginduced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16:1033-1037.
83. Leiro V, Fernandez-Villar A, Valverde D, et al. Influence of glutathione Stransferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 2008; 28:835-839.
84. Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione Stransferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 2007; 47:128-134.
85. Sharma SK, Balamurugan A, Saha PK, et al. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 2002; 166:916-919.
86. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486.
87. Chung WH, Hung SI, Chen YT. Genetic predisposition of life-threatening antiepileptic-induced skin reactions. Expert Opin Drug Saf 2010; 9:15-21.
88. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepineinduced cutaneous adverse drug reactions. Pharmacogenet Genom 2006; 16:297-306.
89. Lonjou C, Borot N, Sekula P, et al. A European study of HLA-B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genom 2008; 18:99-107.
90. Man CB, Kwan P, Baum L, et al. Association between HLA-B-1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48:1015-1018.
91. Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B-1502 allele in Thai population. Epilepsia 2008; 49:2087-2091.
92. Mehta TY, Prajapati LM, Mittal B, et al. Association of HLA-B-1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol 2009; 75:579-582.
93. Alfirevic A, Jorgensen AL, Williamson PR, et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7:813-818.
94. Kaniwa N, Saito Y, Aihara M, et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-1622.
95. Kim SH, Lee KH, Kim SH, et al. HLA genotypes in Korean patients with carbamazepine-induced severe cutaneous adverse reaction. Korean J Asthma Allergy Clin Immunol 2009; 29:S248.
96. Kazeem GR, Cox C, Aponte J, et al. High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients. Pharmacogenet Genom 2009; 19:661-665.
97. Alfirevic A, Mills T, Harrington P, et al. Serious carbamazepine-induced hypersensitivity reactions associated with the HSP70 gene cluster. Pharmacogenet Genom 2006; 16:287-296.
98. Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009; 22:144-149.
99. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359:1121-1122.
100. Mallal S, Nolan D, Witt C, et al. Association between presence of HLAB -5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reversetranscriptase inhibitor abacavir. Lancet 2002; 359:727-732.
101. Mallal S, Phillips E, Carosi G, et al. HLA-B-5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
102. Rauch A, Nolan D, Martin A, et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43:99-102.
103. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B-5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci U S A 2004; 101:4180-4185.
104. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5:203-211.
105. Park WB, Choe PG, Song KH, et al. Should HLA-B-5701 screening be performed in every ethnic group before starting abacavir? Clin Infect Dis 2009; 48:365-367.
106. Hughes DA, Vilar FJ, Ward CC, et al. Cost-effectiveness analysis of HLA B-5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14:335-342.
107. Nolan D. HLA-B-5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci 2009; 46:153-165.
108. Hung SI, Chung WH, Liou LB, et al. HLA-B-5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134-4139.
109. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction? Singapore Med J 2008; 49:384-387.
110. Dainichi T, Uchi H, Moroi Y, Furue M. Stevens-Johnson syndrome, druginduced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity? Dermatology 2007; 215:86-88.
111. Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B-5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genom 2009; 19:704-709.
112. Kang HR, Jee YK, Kim SH, et al. A Korean study of HLA in allopurinol induced severe cutaneous adverse reactions. Korean J Asthma Allergy Clin Immunol 2009; 29:S249.
113. Ueta M, Sotozono C, Tokunaga K, et al. Strong association between HLAA -0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143:367-368.